Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Current Assets (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Current Assets for 4 consecutive years, with $270.5 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Current Assets rose 41.94% year-over-year to $270.5 million, compared with a TTM value of $270.5 million through Sep 2023, up 41.94%, and an annual FY2022 reading of $285.2 million, up 70.84% over the prior year.
  • Current Assets was $270.5 million for Q3 2023 at Terns Pharmaceuticals, down from $288.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $299.7 million in Q1 2023 and bottomed at $90.9 million in Q4 2020.
  • Average Current Assets over 4 years is $204.4 million, with a median of $188.7 million recorded in 2021.
  • The sharpest move saw Current Assets dropped 23.69% in 2022, then surged 102.18% in 2023.
  • Year by year, Current Assets stood at $90.9 million in 2020, then skyrocketed by 83.7% to $166.9 million in 2021, then surged by 70.84% to $285.2 million in 2022, then fell by 5.17% to $270.5 million in 2023.
  • Business Quant data shows Current Assets for TERN at $270.5 million in Q3 2023, $288.3 million in Q2 2023, and $299.7 million in Q1 2023.